PTC Q3 2026 revenue rises 77% to $358 million
PTC Therapeutics reported record third-quarter revenue, significantly raising full-year guidance. The company secured regulatory approval for its Fabry gene therapy, indicating ongoing pipeline diversification and success of the Sephience launch.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed